- Home
- SILO vs VRAX Comparison
SILO vs VRAX Comparison
Compare SILO & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- VRAX
- Stock Information
- Founded
- SILO 2010
- VRAX 2013
- Country
- SILO United States
- VRAX United Kingdom
- Employees
- SILO N/A
- VRAX N/A
- Industry
- SILO Apparel
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SILO Consumer Discretionary
- VRAX Health Care
- Exchange
- SILO Nasdaq
- VRAX Nasdaq
- Market Cap
- SILO 4.3M
- VRAX 4.7M
- IPO Year
- SILO N/A
- VRAX 2022
- Fundamental
- Price
- SILO $0.64
- VRAX $0.81
- Analyst Decision
- SILO
- VRAX Strong Buy
- Analyst Count
- SILO 0
- VRAX 1
- Target Price
- SILO N/A
- VRAX $3.00
- AVG Volume (30 Days)
- SILO 2.2M
- VRAX 37.2K
- Earning Date
- SILO 08-12-2025
- VRAX 02-05-2025
- Dividend Yield
- SILO N/A
- VRAX N/A
- EPS Growth
- SILO N/A
- VRAX N/A
- EPS
- SILO N/A
- VRAX N/A
- Revenue
- SILO $72,102.00
- VRAX $84,872.00
- Revenue This Year
- SILO $1.86
- VRAX $5,169.18
- Revenue Next Year
- SILO N/A
- VRAX $66.97
- P/E Ratio
- SILO N/A
- VRAX N/A
- Revenue Growth
- SILO N/A
- VRAX 7.03
- 52 Week Low
- SILO $0.41
- VRAX $0.75
- 52 Week High
- SILO $4.50
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- SILO 51.15
- VRAX 31.75
- Support Level
- SILO $0.60
- VRAX $0.75
- Resistance Level
- SILO $0.61
- VRAX $0.85
- Average True Range (ATR)
- SILO 0.06
- VRAX 0.07
- MACD
- SILO 0.02
- VRAX -0.01
- Stochastic Oscillator
- SILO 43.36
- VRAX 6.57
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.